ECSP13013036A - Alfa glucosidasa ácida modificada con procesamiento acelerado - Google Patents

Alfa glucosidasa ácida modificada con procesamiento acelerado

Info

Publication number
ECSP13013036A
ECSP13013036A ECSP13013036A ECSP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A EC SP13013036 A ECSP13013036 A EC SP13013036A
Authority
EC
Ecuador
Prior art keywords
accelerated processing
modified acid
alfa
glucosidase modified
alfa glucosidase
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
William M Canfield
Rodney J Moreland
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013036(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of ECSP13013036A publication Critical patent/ECSP13013036A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ECSP13013036 2011-04-22 2013-11-21 Alfa glucosidasa ácida modificada con procesamiento acelerado ECSP13013036A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478336P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
ECSP13013036A true ECSP13013036A (es) 2015-04-30

Family

ID=46000406

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013036 ECSP13013036A (es) 2011-04-22 2013-11-21 Alfa glucosidasa ácida modificada con procesamiento acelerado

Country Status (24)

Country Link
US (1) US20140186326A1 (OSRAM)
EP (1) EP2699676A1 (OSRAM)
JP (2) JP2014513952A (OSRAM)
KR (1) KR20140037082A (OSRAM)
CN (1) CN103797115A (OSRAM)
AU (1) AU2012245280A1 (OSRAM)
BR (1) BR112013026976A2 (OSRAM)
CA (1) CA2833371A1 (OSRAM)
CL (1) CL2013003010A1 (OSRAM)
CO (1) CO6811810A2 (OSRAM)
CR (1) CR20130555A (OSRAM)
EC (1) ECSP13013036A (OSRAM)
GT (1) GT201300252A (OSRAM)
IL (1) IL228871A0 (OSRAM)
MA (1) MA35125B1 (OSRAM)
MX (1) MX2013012345A (OSRAM)
NI (1) NI201300110A (OSRAM)
PE (1) PE20140617A1 (OSRAM)
PH (1) PH12013502149A1 (OSRAM)
RU (1) RU2013151875A (OSRAM)
SG (2) SG194486A1 (OSRAM)
TN (1) TN2013000427A1 (OSRAM)
WO (1) WO2012145644A1 (OSRAM)
ZA (1) ZA201307696B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
KR20250004926A (ko) 2014-09-30 2025-01-08 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
US11262348B2 (en) 2015-11-06 2022-03-01 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
KR102790256B1 (ko) 2016-03-30 2025-04-04 아미쿠스 세라퓨틱스, 인코포레이티드 고 m6p 재조합 단백질의 선택 방법
WO2017173060A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
US11339406B2 (en) 2016-09-12 2022-05-24 Genethon Acid-alpha glucosidase variants and uses thereof
DK3624831T5 (da) 2017-05-15 2024-09-02 Amicus Therapeutics Inc Rekombinant human sur alfa-glucosidase
BR112019025888A2 (pt) 2017-06-07 2020-06-30 Regeneron Pharmaceuticals, Inc. polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
MY206284A (en) 2018-05-17 2024-12-06 Regeneron Pharma Anti-cd63 antibodies, conjugates, and uses thereof
EP3996696A1 (en) 2019-07-09 2022-05-18 Genethon Treatment of glycogen storage disease (gsd)
PH12022551229A1 (en) * 2019-11-19 2023-07-31 Asklepios Biopharmaceutical Inc Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5952516A (en) 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
IL135578A0 (en) 1997-10-29 2001-05-20 Genzyme Corp Compositions and methods for treating lysosomal storage disease
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase
AU3113700A (en) * 1998-12-07 2000-06-26 Genzyme Corporation Treatment of pompe's disease
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
ES2399323T3 (es) 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
WO2004064750A2 (en) * 2003-01-22 2004-08-05 Duke University Improved constructs for expressing lysosomal polypeptides
US20100196345A1 (en) 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
EP3346010A1 (en) 2003-06-24 2018-07-11 Genzyme Corporation Novel beta-actin and rps21 promoters and uses thereof
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
WO2008063511A2 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
HUE044381T2 (hu) 2008-12-16 2019-10-28 Genzyme Corp Szintetikus intermedierek oligoszacharid-fehérje konjugátumok elõállításához
WO2010096369A1 (en) * 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof

Also Published As

Publication number Publication date
MX2013012345A (es) 2015-05-07
ZA201307696B (en) 2014-07-30
RU2013151875A (ru) 2015-05-27
PH12013502149A1 (en) 2019-09-02
CO6811810A2 (es) 2013-12-16
TN2013000427A1 (en) 2015-03-30
US20140186326A1 (en) 2014-07-03
PE20140617A1 (es) 2014-05-28
MA35125B1 (fr) 2014-05-02
CN103797115A (zh) 2014-05-14
SG10201605874TA (en) 2016-09-29
NI201300110A (es) 2014-02-28
CR20130555A (es) 2013-12-09
JP2014513952A (ja) 2014-06-19
EP2699676A1 (en) 2014-02-26
IL228871A0 (en) 2013-12-31
BR112013026976A2 (pt) 2019-09-24
CL2013003010A1 (es) 2014-03-07
CA2833371A1 (en) 2012-10-26
WO2012145644A1 (en) 2012-10-26
SG194486A1 (en) 2013-12-30
JP2017035091A (ja) 2017-02-16
KR20140037082A (ko) 2014-03-26
AU2012245280A1 (en) 2013-11-07
GT201300252A (es) 2015-02-09

Similar Documents

Publication Publication Date Title
ECSP13013036A (es) Alfa glucosidasa ácida modificada con procesamiento acelerado
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
UY34577A (es) Método para estabilizar fibra de lignina y su posterior conversión en fibra de carbono
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
HUE039816T2 (hu) Lignocellulózos biomassza egylépcsõs autohidrolízis és C5 kikerülésével történõ enzimatikus hidrolízis és poszthidrolízis alkalmazásával történõ feldolgozásának eljárásai
BR112015009042A2 (pt) populações de célula renal e usos das mesmas
EA201690718A1 (ru) Способ обработки целлюлозосодержащей биомассы
IL222824B (en) Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
UA110813C2 (uk) Лікування ліподистрофії
MX375786B (es) Biosintesis microbiana de ergotioneina.
MX2013010557A (es) Anticuerpo del factor tisular humano y usos de este.
PL2865038T3 (pl) Elektroda dwubiegunowa i sposób jej wytwarzania
BR112015008111A2 (pt) célula de levedura geneticamente modificada, e , método para a produção de 3hp.
MX2015012875A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
AR085793A1 (es) Metodo para producir una fibra de lignina
MX2016003737A (es) Microorganismo recombinante para la mejora de produccion de productos quimicos finos.
MX377149B (es) Microorganismo recombinante para la produccion mejorada de productos quimicos finos.
AR093986A1 (es) Cuerpos de carbono ferromagneticos y proceso de produccion
UY33992A (es) Métodos para modificar la biosintesis de la lignina y mejorar la digestibilidad
UY34377A (es) Proceso para producir peróxido de hidrógeno
EA201590718A1 (ru) Способы получения макроциклических депсипептидов с использованием ацетальальдегида и новые промежуточные соединения
IN2014DN07958A (OSRAM)
MX2012010382A (es) Modulacion de acuaporinas con relaxina.
BR112013023144A2 (pt) método de tratamento de couro cabeludo
BR112013030164A2 (pt) pilha de combustível e processo de realização de uma pilha de combustível.